A randomised, multi-stage phase II/III study of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal cancer (the STAR trial)
Record ID 32011000720
English
Details
Project Status:
Ongoing
URL for project:
https://www.journalslibrary.nihr.ac.uk/programmes/hta/099121/#/
Anticipated Publish Date:
2022
Requestor:
NIHR Health Technology Assessment programme
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England, United Kingdom
MeSH Terms
- Indoles
- Kidney Neoplasms
- Pyrroles
- Sunitinib
- Carcinoma, Renal Cell
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Protein Kinase Inhibitors
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.